Quality of Life, Cost-effectiveness of Radioiodine Ablation in Thyroid Cancer Assessed

Share this content:
Recombinant human TSh (rhTSH)  is not cost-effective for thyroid cancer and would likely not be used in practice.
Recombinant human TSh (rhTSH) is not cost-effective for thyroid cancer and would likely not be used in practice.

While recombinant human TSh (rhTSH) avoids the transient thyroid hormone withdrawal (THW) deterioration of health-related qualify of life (HRQoL) in patients with thyroid cancer, it is not cost-effective and would likely not be used in practice, according to an article published online ahead of print in the Journal of Clinical Oncology.

In the phase 3 ESTIMABL trial, the thyroid ablation rate was equivalent for both thyroid hormone withdrawal (THW) and rhTSH methods and the two iodine-131 (131I or 3.7 GBq).

A total of 752 patients with thyroid cancer were assessed, from the time of random assignment to a follow-up visit at 8±2 months. Resource use (hospitalization for 131I administration, rhTSH, sick leave, and transportation) was collected prospectively.

RELATED: Germline HABP2 Mutation Associated with Familial Nonmedullary Thyroid Cancer

At 131I administration, patients experienced a clinically significant deterioration of HRQoL with THW, but it remained stable with rhTSH. The deterioration was transient with no difference 3 months later. rhTSH was more effective than THW in terms of quality-adjusted life years, but was more expensive.

The use of 1.1 GBq of 131I instead of 3.7 GBq reduced per-patient costs by $1,018 but with slightly decreased efficacy.

Reference

  1. Borget I, Bonastre J, Catargi B, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2015.61.6722.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters